IDNA vs. CNCR
IDNA (iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds - IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index while CNCR tracks the Loncar Cancer Immunotherapy Index. Both are passively managed. IDNA charges 0.47%/yr vs 0.79%/yr for CNCR.
Performance
IDNA vs. CNCR - Performance Comparison
Loading charts...
Returns By Period
IDNA
- 1D
- -1.79%
- 1M
- 11.15%
- 6M
- 19.72%
- YTD
- 26.34%
- 1Y
- 57.08%
- 3Y*
- 12.75%
- 5Y*
- -6.42%
- 10Y*
- —
CNCR
- 1D
- 0.00%
- 1M
- 0.00%
- 6M
- —
- YTD
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
IDNA vs. CNCR - Yearly Performance Comparison
IDNA vs. CNCR - Sectors Allocation Comparison
Sectors
IDNA
CNCR
Healthcare
Industrials
-
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Financial Services
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
IDNA
CNCR
Industrials
IDNA
CNCR
-
Basic Materials
IDNA
-
CNCR
-
Communication Services
IDNA
-
CNCR
-
Consumer Cyclical
IDNA
-
CNCR
-
Consumer Defensive
IDNA
-
CNCR
-
Energy
IDNA
-
CNCR
-
Financial Services
IDNA
-
CNCR
Real Estate
IDNA
-
CNCR
-
Technology
IDNA
-
CNCR
-
Utilities
IDNA
-
CNCR
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
IDNA vs. CNCR — Risk / Return Rank
IDNA
CNCR
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
IDNA vs. CNCR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| IDNA | CNCR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | 1.36 | — | — |
| Calmar ratioReturn relative to maximum drawdown | 5.38 | — | — |
| Martin ratioReturn relative to average drawdown | 14.96 | — | — |
Loading charts...
Drawdowns
IDNA vs. CNCR - Drawdown Comparison
The maximum IDNA drawdown since its inception was -68.26%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for IDNA and CNCR.
Loading charts...
Drawdown Indicators
| IDNA | CNCR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -68.26% | 0.00% | -68.26% |
Max Drawdown (1Y)Largest decline over 1 year | -10.66% | — | — |
Max Drawdown (3Y)Largest decline over 3 years | -29.46% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -68.26% | — | — |
Current DrawdownCurrent decline from peak | -37.71% | 0.00% | -37.71% |
Average DrawdownAverage peak-to-trough decline | -36.28% | 0.00% | -36.28% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.83% | — | — |
Volatility
IDNA vs. CNCR - Volatility Comparison
Loading charts...
Volatility by Period
| IDNA | CNCR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.23% | — | — |
Volatility (6M)Calculated over the trailing 6-month period | 18.68% | — | — |
Volatility (1Y)Calculated over the trailing 1-year period | 25.27% | 0.00% | +25.27% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 28.52% | 0.00% | +28.52% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 29.51% | 0.00% | +29.51% |
IDNA vs. CNCR - Expense Ratio Comparison
IDNA has a 0.47% expense ratio, which is lower than CNCR's 0.79% expense ratio.
Dividends
IDNA vs. CNCR - Dividend Comparison
IDNA's dividend yield for the trailing twelve months is around 0.85%, while CNCR has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
CNCR Loncar Cancer Immunotherapy ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 0.85% | 1.18% | 0.98% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% |
Frequently Asked Questions
On fees, IDNA is cheaper at 0.47% per year. The better choice depends on whether you care most about return, fees, risk, or income.
IDNA is cheaper with a 0.47% expense ratio, compared with 0.79% for CNCR.
IDNA has the higher dividend yield at 0.85%, compared with 0.00% for CNCR.
IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index, while CNCR tracks Loncar Cancer Immunotherapy Index. They also come from different issuers: iShares and Exchange Traded Concepts. Their fees differ too: 0.47% for IDNA and 0.79% for CNCR.
Find the right allocation for IDNA and CNCR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer